Abstract Number: 581 • 2019 ACR/ARP Annual Meeting
Allograft Inflammatory factor-1 Drives Th17 Like Pathologic Signature and Predict Poor Response to TNF Inhibitor in Ankylosing Spondylitis
Background/Purpose: Ankylosing spondylitis (AS) is an inflammatory disease that commonly treated with TNF inhibitors for controlling active inflammation. To predict treatment response to TNF inhibitors…Abstract Number: 620 • 2019 ACR/ARP Annual Meeting
Arterial Elasticity by 2 Dimensional Circumferential Strain and Beta Stiffness Index in Patients with Ankylosing Spondylitis
Background/Purpose: Ankylosing spondylitis (AS) is associated with elevated risk of cardiovascular disease (CVD) and increased mortality. Arterial stiffness is associated with atherosclerosis and CV events.…Abstract Number: 1509 • 2019 ACR/ARP Annual Meeting
Impact of Age and Disease Duration on the Response to IL-17A Inhibitor (Secukinumab) Treatment in Ankylosing Spondylitis: Pooled Results from the Phase 3 MEASURE Studies
Background/Purpose: Ankylosing spondylitis (AS), a chronic inflammatory disease involving the sacroiliac joints and spine, is associated with pain, stiffness, disability, and reduced quality of life.1,2…Abstract Number: 2211 • 2019 ACR/ARP Annual Meeting
What Are the Consequences of Spinal Ankylosis on the Bone Trabecular Fragility Assessed on CT- scan in Patients with Ankylosing Spondylitis?
Background/Purpose: Computed Tomography (CT) is sometimes performed during the follow up of patients with ankylosing spondylitis (AS) to screen comorbidities or complications. Thoracic or thoraco-abdomino-pelvic…Abstract Number: 583 • 2019 ACR/ARP Annual Meeting
A Biomarker of Type VI Collagen Degradation (C6M) Is Associated with Changes in ASDAS MRI Measures of Inflammation in Patients with Axial Spondyloarthritis During TNF Inhibitor Therapy
Background/Purpose: Axial spondyloarthritis (AxSpa) is characterized by inflammation in the sacroiliac joints and spine and associated with extracellular matrix (ECM) remodelling of affected tissues. Type…Abstract Number: 625 • 2019 ACR/ARP Annual Meeting
Associations of Work-Related Abilities with Disability in Ankylosing Spondylitis
Background/Purpose: Withdrawal from the workforce is 3.1 times higher in patients with Ankylosing Spondylitis (AS) compared to the general population [Boonen A, et al. 2001]. Functional…Abstract Number: 1517 • 2019 ACR/ARP Annual Meeting
Effect of Long-Term Treatment with Secukinumab on Cardio-Metabolic Profile in Patients with Active Ankylosing Spondylitis and Psoriatic Arthritis: Pooled 3 Year Analysis
Background/Purpose: Systemic inflammation may influence cardio-metabolic profiles and increases the risk of CV disorders in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients (pts)1. Treatment…Abstract Number: 2460 • 2019 ACR/ARP Annual Meeting
Frailty in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis: Data from a National Claims Database
Background/Purpose: Frailty, a state of decreased homeostatic reserve, is associated with increased disability and mortality, independent of age. Frailty has been evaluated in large datasets…Abstract Number: 584 • 2019 ACR/ARP Annual Meeting
Radiographic Association of Hip and SI Joints in Ankylosing Spondylitis Patients
Background/Purpose: The modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) is a representative tool for assessing radiographic progression in spine of ankylosing spondylitis (AS) patients. However,…Abstract Number: 626 • 2019 ACR/ARP Annual Meeting
Are There Really Differences Between Non-radiographic and Radiographic Axial Spondyloarthritis? Data from the Spanish Atlas
Background/Purpose: Most research studies support the fact that both, radiographic and non-radiographic axial spondyloarthritis (r-axSpA and nr-axSpA), share similar clinical characteristics and equivalent burden of…Abstract Number: 1519 • 2019 ACR/ARP Annual Meeting
Predicting Response to Biologic Therapy in Patients with Axial Spondyloarthritis (axSpA)
Background/Purpose: In axial spondyloarthritis (axSpA), the clinical benefits of TNF inhibition (TNFi) are well documented although, by design, most studies report average benefits in groups…Abstract Number: 2774 • 2019 ACR/ARP Annual Meeting
Cluster-based Spondyloarthritis Phenotypes Defined at Baseline Are Predictive of Different Severity Outcomes at 5-Year in the DESIR Cohort
Background/Purpose: The course of axial spondyloarthritis (SpA) is heterogeneous and remains to be better defined. DESIR is a longitudinal French cohort of early undifferentiated axial…Abstract Number: 585 • 2019 ACR/ARP Annual Meeting
Effect of Testosterone on Spinal Ankylosis in Ankylosing Spondylitis : in Vivo and in Vitro
Background/Purpose: Ankylosing spondylitis (AS) is a predominantly male disease and spinal ankylosis more severely affect male AS1 suggesting role of testosterone on spinal ankylosis. In…Abstract Number: 628 • 2019 ACR/ARP Annual Meeting
Pain Perception and Opiate Use Among Patients with Inflammatory Arthritis
Background/Purpose: Pain is the most common symptom among patients with inflammatory arthritis (IA) and residual pain is common in patients IA despite appropriate treatment. Opiate…Abstract Number: 1521 • 2019 ACR/ARP Annual Meeting
Ixekizumab Is Effective in the Treatment of Radiographic Axial Spondyloarthritis Regardless of the Level of C-Reactive Protein or Magnetic Resonance Imaging Scores
Background/Purpose: IL-17 plays an important role in the pathogenesis of radiographic axial spondyloarthritis (r-axSpA). Elevated CRP levels in serum predict response to TNF inhibitors (TNFi).1-4…
- 1
- 2
- 3
- …
- 35
- Next Page »